Please do your own DD using FA +TA
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://www.anavex.com/?news=anavex-receives-notice-of-allowance-for-u-s-patent-application-related-to-anavex-2-73
NEW YORK, NY, August 12, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. Upon issuance, the patent will provide intellectual property (IP) protection until at least 2035. ANAVEX2-73 is the subject of an ongoing Phase 2a clinical trial for the treatment of Alzheimer’s disease.
The allowed patent claims cover formulations and treatments that provide particular coverage relating to improved sigma receptor ligands and their use.
“This patent is a valuable addition to our IP portfolio and covers innovations we have made in our development efforts for ANAVEX 2-73 and beyond,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We have filed numerous patent applications to cover promising compositions and therapies, including those pertaining to ANAVEX 2-73, in keeping with our commitment to a comprehensive IP protection strategy.”
Additional U.S. patent applications filed for pharmaceutical composition of matter for ANAVEX 2-73 will, if granted, provide further patent protection until at least 2035. An additional patent application on file for ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil, if granted, will provide protection for composition of matter until at least 2033.
The USPTO issues a Notice of Allowance after it determines that a patent should be granted for a claimed invention that is novel in comparison to all known technology in existence. Based on the timing of this Notice of Allowance, Anavex expects the patent to be issued by the end of 2015.
www.anavex.com.
Very good to hear that...........so I change my equation to B + K + P = help humanity,
Fletch
PS....Thanks to all those that attended the meeting today and to those that helped us know what went on.......Helping others is most important!
Good to hear from you INH,
Today was a real strange one.......good run up only to finish slightly down. May your catalysts start supporting the price,
Fletch
Did you say Boomsacalaca? ........AVXL!
Fletch
Amazing number of Alzheimer's trials going on in just NYS,
Fletch
PS....nothing as good as AVXL tho!
1. ABT-957 in Subjects with Mild to Moderate Alzheimer's Taking Acetylcholinesterase Inhibitors
Purpose: To evaluate the safety, tolerability, and pharmacokinetics of ABT-957 in people with mild to moderate Alzheimer's disease.
2. AC-1204 for Mild to Moderate Alzheimer's Disease
Purpose: To evaluate the effects of AC-1204 on cognition, activities of daily living, quality of life, pharmacokinetic measures, and safety in people with mild to moderate Alzheimer's disease.
3. Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Purpose: To build a clinical research consortium to test new treatments for people with frontotemporal lobar degeneration.
4. Aerobic & Cognitive Exercise Study (ACES)
Purpose: To clarify the benefits to brain health and thinking processes that result from different forms of exercise.
5. Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4)
Purpose: To test whether an anti-amyloid investigational drug, solanezumab, can slow memory and cognitive decline in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia.
6. AZD0530 in Mild Alzheimer's Disease (Connect Study)
Purpose: To determine the safety and efficacy of the experimental drug AZD0530 in older adults with mild Alzheimer's disease.
7. AZD3293 in Early Alzheimer's Disease (AMARANTH)
Purpose: To assess the efficacy and safety of AZD3293 as a possible treatment for early Alzheimer´s disease.
8. BAN2401 for Early Alzheimer's Disease
Purpose: To determine the effectiveness of the experimental drug BAN2401 as a possible treatment for people with mild cognitive impairment or mild Alzheimer's disease.
9. Benfotiamine in Alzheimer's Disease
Purpose: To determine whether treatment with benfotiamine, a dietary supplement, minimizes cognitive decline in older adults with amnestic mild cognitive impairment or mild Alzheimer's disease.
10. BI 409306 for Cognitive Impairment Due to Alzheimer's Disease
Purpose: To test the experimental drug BI 409306 in people with cognitive impairment due to Alzheimer's disease.
11. BI 409306 for Early-Stage Alzheimer's Disease
Purpose: To test the experimental drug BI 409306 in people with early Alzheimers disease.
12. Crenezumab for Mild to Moderate Alzheimer Disease
Purpose: To evaluate the safety and tolerability of crenezumab in older adults with mild to moderate Alzheimer's disease.
13. Dominantly Inherited Alzheimer Network (DIAN)
Purpose: To identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
14. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia (DIAN TU)
Purpose: To assess the safety, tolerability, and biomarker efficacy of gantenerumab and solanezumab in individuals who have a genetic mutation for autosomal-dominant Alzheimer's disease.
15. EMERGE: Aducanumab (BIIB037) for Early Alzheimer's Disease
Purpose: To evaluate treatment of early Alzheimer's disease with the experimental drug aducanumab (BIIB037).
16. ENGAGE: Aducanumab (BIIB037) for Early Alzheimer's Disease
Purpose: To evaluate treatment of early Alzheimer's disease with the experimental drug aducanumab (BIIB037).
17. Gantenerumab for Mild Alzheimer Disease
Purpose: To evaluate the efficacy and safety of the experimental drug gantenerumab as a possible treatment for people with mild Alzheimer disease.
18. Hispanic Caregiver Intervention Effectiveness Study
Purpose: To compare two dementia caregiver interventions to determine which is most effective for Hispanic caregivers in New York City.
19. Home-Delivered Intervention for Depressed, Cognitively Impaired Elders
Purpose: To test the efficacy of Problem Adaptation Therapy (PATH), a home-delivered psychosocial intervention for elders with major depression, memory problems, and disability.
20. Imaging of Cognition, Learning, and Memory in Aging
Purpose: To study how the brain functions when it performs explicit memory tasks and how this changes as a function of aging.
21. Longitudinal Evaluation of Familial Frontotemporal Dementia (LEFFTDS)
Purpose: To learn about thinking and behavior in families in which one or more relatives has a genetic mutation associated with frontotemporal dementia.
22. Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
Purpose: To determine whether positron emission tomography (PET) scanning can help distinguish patients with early Alzheimer's changes in their brains from those having other causes of cognitive impairment more accurately than current clinical practices.
23. MK-7622 in People with Alzheimer's Disease Taking Donepezil
Purpose: To test the efficacy and safety of MK-7622 as an add-on therapy to donepezil in people with mild to moderate Alzheimer's disease.
24. MK-8931 for Amnestic Mild Cognitive Impairment (APECS)
Purpose: To assess MK-8931 as a possible treatment for amnestic mild cognitive impairment due to Alzheimer's disease.
25. NOBLE: T-817MA for Mild to Moderate Alzheimer's Disease
Purpose: To evaluate the efficacy of the experimental drug T-817MA as a potential treatment for people with mild to moderate Alzheimer's disease.
26. Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Older Adults
Purpose: To determine if a worsened sense of smell can identify older people who might benefit from treatment with the Alzheimer's drug donepezil.
27. PET Imaging with 18F-AV-1451
Purpose: To evaluate the characteristics of the brain imaging agent 18F-AV-1451 in cognitively healthy volunteers and in people with mild cognitive impairment or Alzheimer's disease.
28. Prediction of Mild Cognitive Impairment and Pioglitazone to Delay Its Onset (TOMMORROW)
Purpose: To develop a biomarker that predicts the risk of mild cognitive impairment due to Alzheimer's disease and to test the drug pioglitazone to delay the onset of MCI.
29. Riluzole for Mild Alzheimer's Disease
Purpose: To test the safety and effectiveness of the drug riluzole for treating mild Alzheimer's disease.
30. Sleep-Disordered Breathing and Alzheimer's Disease Prevention (SNAP)
Purpose: To examine the relationship between sleep-disordered breathing and Alzheimer's disease in cognitive normal older adults.
31. STARBEAM: Lu AE58054 in People with Mild to Moderate Alzheimer's Disease Taking Donepezil
Purpose: To test Lu AE58054 as an add-on therapy to donepezil in people with mild to moderate Alzheimer's disease.
32. STARSHINE: Lu AE58054 in People with Mild to Moderate Alzheimer's Disease Taking Donepezil
Purpose: To test the drug Lu AE58054 as an add-on therapy to donepezil for people with mild to moderate Alzheimer's disease.
33. Treatment of Psychosis and Agitation in Alzheimer's Disease
Purpose: To test lithium as a treatment for psychosis and agitation in older adults with Alzheimer's disease.
https://www.nia.nih.gov/alzheimers/topics/treatment
Lots of negative stuff said lately about TA. I say in my profile that I use both FA and TA. So far I've only used TA to help make good low buys. I'm now getting close to having enough AVXL that I may sell some on the next spike top..........Might!
Some are showing anger and are saying traders are holding us back. Not sure who is but a seller is......not me,
Fletch
Edit: My first buy was in June but only a small starter position....
Couldn't agree more,
Fletch
I'm sure not for the gap filling either.........just saying the likely TA target the shorts have now,
Fletch
Much better to spike down quickly than to slowly grind until filled IMHO,
Flech
Hey TD,
My Oklahoma vist is going great............Happy Thanksgiving to all CTIX longs!
Glad to see you as a new mod......recently there has been a sighting of an "E-Tard"......not sure what this means but they are known to torment CTIX longs.....They talk about gaps and may be in great need of an in trial drug for protein miss folding. This may help just a little...but CTIX says....
CYA,
Fletch
Very glad you are back with us.......some think you are just a pumper.......I think you are a very smart investor,
Fletch
"NO ONE but stupid retail is shorting this stock."
I could not agree more........at $14+ or so.....and in Monday Morning hind sight......yes! It was a good short.......due to the parabolic rise....I'm not leaving out the way too naked shorts as well........Now only the real stupid retail would short AVXL here but all IMHO,
Fletch
"Tons of gaps on the way down".........Those are much different than the up gaps for longs.......Tho I don't see any down gaps......
A lot of TA talk earlier.......
A very simple TA rule that can save a bundle..........is a break of a moving average. I like watching the 30 and 50 day moving averages very close.......esp. on the larger caps I own....see my profile for some of them. Ask for more info if you want..........
This moving average rule works........but can cause whipsaws. On small cap bio plays you may want a different plan. On this chart a break of 10 should be a wake up call to maybe sell some,
Fletch
Getting close to being above the important moving averages again...
Hey Jockimo,
It's safe to say we should get 2 to 4 solid up days from here BWDIK. Hard to say much more..........I was very surprised by the range of that huge selloff. Very happy for all us longs now,
Fletch